Defense World
01 Nov 2025, 08:11 UTC · 45w ago
Verdict
Headline takes no side. We score AKBA +0.40 across one claim — moderately bullish.
+0.40moderately bullish
More positive than 63% of ticker scores this week
What the story claims
1 claim · scored −1 bearish … +1 bullish
Ethic Inc. increased its position in Akebia Therapeutics (AKBA) by 243.8% during the second quarter.
So whatSignificant accumulation by an institutional investor suggests confidence in the stock, though a single 13F filing has limited broad market impact.
More positive than 53% of claims this week
Which stocks this story touches
Continue reading
5 related stories
Scored by the NIS engine · methodology.
More positive than 63% of ticker scores this week
A fund significantly increased its holdings in the company, signaling bullish investor sentiment.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
1d ago
−58.6%
Price is moving against the score
$0.9157 vs $2.21 close before publication (Oct 31) · not market-adjusted
AKBA chart →
